SUMO2 Rabbit Polyclonal Antibody
SUMO2 Rabbit Polyclonal Antibody
![]() SUMO2 Polyclonal Antibody |
|||
ABP60553-02ml | Abbkine | 0.2ml | 496.8 EUR |
Description: A polyclonal antibody for detection of SUMO2 from Human, Mouse, Rat. This SUMO2 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human SUMO2 protein at amino acid sequence of 10-90 |
|||
![]() SUMO2 Rabbit pAb |
|||
A1523-100ul | Abclonal | 100 ul | 369.6 EUR |
![]() SUMO2 Rabbit pAb |
|||
A1523-200ul | Abclonal | 200 ul | 550.8 EUR |
![]() SUMO2 Rabbit pAb |
|||
A1523-20ul | Abclonal | 20 ul | 219.6 EUR |
![]() SUMO2 Rabbit pAb |
|||
A1523-50ul | Abclonal | 50 ul | 267.6 EUR |
![]() SUMO2 Rabbit pAb |
|||
A2486-100ul | Abclonal | 100 ul | 369.6 EUR |
![]() SUMO2 Rabbit pAb |
|||
A2486-200ul | Abclonal | 200 ul | 550.8 EUR |
![]() SUMO2 Rabbit pAb |
|||
A2486-20ul | Abclonal | 20 ul | 219.6 EUR |
![]() SUMO2 Rabbit pAb |
|||
A2486-50ul | Abclonal | 50 ul | 267.6 EUR |
![]() SUMO2 Rabbit pAb |
|||
A2571-100ul | Abclonal | 100 ul | 369.6 EUR |
![]() SUMO2 Rabbit pAb |
|||
A2571-200ul | Abclonal | 200 ul | 550.8 EUR |
![]() SUMO2 Rabbit pAb |
|||
A2571-20ul | Abclonal | 20 ul | 219.6 EUR |
![]() SUMO2 Rabbit pAb |
|||
A2571-50ul | Abclonal | 50 ul | 267.6 EUR |
![]() Polyclonal SUMO2/3 Antibody |
|||
APR06632G | Leading Biology | 0.1 mg | 790.8 EUR |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SUMO2/3 . This antibody is tested and proven to work in the following applications: |
|||
![]() Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
|||
DLR-SUMO2-Hu-48T | DL Develop | 48T | 620.4 EUR |
Description: A sandwich quantitative ELISA assay kit for detection of Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
![]() Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
|||
DLR-SUMO2-Hu-96T | DL Develop | 96T | 807.6 EUR |
Description: A sandwich quantitative ELISA assay kit for detection of Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
![]() Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
|||
RD-SUMO2-Hu-48Tests | Reddot Biotech | 48 Tests | 625.2 EUR |
![]() Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
|||
RD-SUMO2-Hu-96Tests | Reddot Biotech | 96 Tests | 867.6 EUR |
![]() Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
|||
RDR-SUMO2-Hu-48Tests | Reddot Biotech | 48 Tests | 652.8 EUR |
![]() Human Small Ubiquitin Related Modifier Protein 2 (SUMO2) ELISA Kit |
|||
RDR-SUMO2-Hu-96Tests | Reddot Biotech | 96 Tests | 907.2 EUR |
![]() SUMO2/3 (SUMO2/3) Antibody |
|||
20-abx008699 | Abbexa |
|
|
![]() SUMO2/3 (SUMO2/3) Antibody |
|||
abx026675-400ul | Abbexa | 400 ul | 627.6 EUR |
![]() SUMO2/3 (SUMO2/3) Antibody |
|||
abx026675-80l | Abbexa | 80 µl | 343.2 EUR |
![]() SUMO2/3 (SUMO2/3) Antibody |
|||
abx026676-400ul | Abbexa | 400 ul | 627.6 EUR |
![]() SUMO2/3 (SUMO2/3) Antibody |
|||
abx026676-80l | Abbexa | 80 µl | 343.2 EUR |
![]() SUMO2/3 (SUMO2/3) Antibody |
|||
abx026683-400ul | Abbexa | 400 ul | 627.6 EUR |
![]() SUMO2/3 (SUMO2/3) Antibody |
|||
abx026683-80l | Abbexa | 80 µl | 343.2 EUR |
![]() SUMO2/3 (SUMO2/3) Antibody |
|||
abx238390-100ug | Abbexa | 100 ug | 610.8 EUR |
![]() SUMO2/3 (SUMO2/3) Antibody |
|||
abx238391-100ug | Abbexa | 100 ug | 661.2 EUR |
![]() SUMO2 Antibody |
|||
CSB-PA099258- | Cusabio | 402 EUR | |
Description: A polyclonal antibody against SUMO2. Recognizes SUMO2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:3000, IHC:1:50-1:100 |
|||
![]() SUMO2 Antibody |
|||
CSB-PA099258-100ul | Cusabio | 100ul | 379.2 EUR |
Description: A polyclonal antibody against SUMO2. Recognizes SUMO2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:3000, IHC:1:50-1:100 |
|||
![]() SUMO2 Antibody |
|||
1-CSB-PA05009A0Rb | Cusabio |
|
|
Description: A polyclonal antibody against SUMO2. Recognizes SUMO2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
![]() SUMO2 Antibody |
|||
DF7024 | Affbiotech | 200ul | 420 EUR |
![]() SUMO2 Antibody |
|||
1-CSB-PA022949GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against SUMO2. Recognizes SUMO2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
|||
![]() SUMO2 antibody |
|||
70R-20650 | Fitzgerald | 50 ul | 522 EUR |
Description: Rabbit polyclonal SUMO2 antibody |
|||
![]() SUMO2 Antibody |
|||
32722-100ul | SAB | 100ul | 302.4 EUR |
![]() SUMO2 antibody |
|||
38405-100ul | SAB | 100ul | 302.4 EUR |
![]() SUMO2 antibody |
|||
10R-1181 | Fitzgerald | 100 ul | 379.2 EUR |
Description: Mouse monoclonal SUMO2 antibody |
|||
![]() SUMO2 Antibody |
|||
ABD7024 | Lifescience Market | 100 ug | 525.6 EUR |
![]() SUMO2 Antibody |
|||
F52344-0.08ML | NSJ Bioreagents | 0.08 ml | 165 EUR |
![]() SUMO2 Antibody |
|||
F42016-0.08ML | NSJ Bioreagents | 0.08 ml | 165 EUR |
![]() SUMO2 Antibody |
|||
F42497-0.08ML | NSJ Bioreagents | 0.08 ml | 165 EUR |
![]() SUMO2 Antibody |
|||
F42497-0.4ML | NSJ Bioreagents | 0.4 ml | 389 EUR |
![]() SUMO2 Antibody |
|||
F42523-0.4ML | NSJ Bioreagents | 0.4 ml | 379 EUR |
![]() SUMO2 Antibody |
|||
V2860-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() SUMO2 Antibody |
|||
V2860-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() SUMO2 Antibody |
|||
V2860IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() SUMO2 Antibody |
|||
V2860SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() SUMO2 Antibody |
|||
V2861-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO1 and unlike SUMO1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() SUMO2 Antibody |
|||
V2861-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO1 and unlike SUMO1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() SUMO2 Antibody |
|||
V2861IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO1 and unlike SUMO1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() SUMO2 Antibody |
|||
V2861SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO1 and unlike SUMO1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() SUMO2 Antibody |
|||
V7051-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. |
|||
![]() SUMO2 Antibody |
|||
V7051-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. |
|||
![]() SUMO2 Antibody |
|||
V7051IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. |
|||
![]() SUMO2 Antibody |
|||
V7051SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. |
|||
![]() Anti-Sumo2/3 Rabbit Monoclonal Antibody |
|||
M01282-2 | BosterBio | 100ug/vial | 476.4 EUR |
Description: Rabbit Monoclonal Sumo2/3 Antibody. Validated in IF, WB and tested in Human, Mouse, Rat. |
|||
![]() Polyclonal SUMO2 Antibody (aa44-93) |
|||
APR03220G | Leading Biology | 0.05ml | 580.8 EUR |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SUMO2 (aa44-93). This antibody is tested and proven to work in the following applications: |
|||
![]() Polyclonal SUMO2 Antibody (C-term) |
|||
APR03744G | Leading Biology | 0.1ml | 580.8 EUR |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SUMO2 (C-term). This antibody is tested and proven to work in the following applications: |
|||
![]() SUMO2 |
|||
E541-030 | EnoGene | 100ug | 411.6 EUR |
![]() Polyclonal SUMO2/3 Antibody (N-term) |
|||
APR03665G | Leading Biology | 0.1ml | 580.8 EUR |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SUMO2/3 (N-term). This antibody is tested and proven to work in the following applications: |
|||
![]() Polyclonal SUMO2/3 Antibody (C-term) |
|||
APR03666G | Leading Biology | 0.1ml | 580.8 EUR |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SUMO2/3 (C-term). This antibody is tested and proven to work in the following applications: |
|||
![]() SUMO2 Conjugated Antibody |
|||
C32722 | SAB | 100ul | 476.4 EUR |
![]() SUMO2/3 antibody |
|||
70R-50404 | Fitzgerald | 100 ul | 292.8 EUR |
Description: Purified Polyclonal SUMO2/3 antibody |
|||
![]() SUMO2/3 antibody |
|||
70R-30820 | Fitzgerald | 100 ug | 392.4 EUR |
Description: Rabbit polyclonal SUMO2/3 antibody |
|||
![]() SUMO2/3 antibody |
|||
70R-30839 | Fitzgerald | 100 ug | 392.4 EUR |
Description: Rabbit polyclonal SUMO2/3 antibody |
|||
![]() Human SUMO2 Antibody |
|||
32621-05111 | AssayPro | 150 ug | 313.2 EUR |
![]() SUMO2/3 Antibody |
|||
5755-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: SUMO2/3 Antibody: Small ubiquitin-like modifiers (SUMOs) are a family of small, related proteins (Sumo-1/2/3/4) that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation, which is a major regulator of protein function in cellular processes such as nuclear transport, transcriptional regulation, apoptosis and protein stability. All SUMO proteins localize to the nucleus and are covalently conjugated, affecting protein structure, function and interactions. SUMO2 and 3 are 96% identical and are more mobile within nucleus relative to SUMO1. Specific functional differences between SUMO1 and SUMO2 and 3 remain to be identified. |
|||
![]() SUMO2/3 Antibody |
|||
5755-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: SUMO2/3 Antibody: Small ubiquitin-like modifiers (SUMOs) are a family of small, related proteins (Sumo-1/2/3/4) that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation, which is a major regulator of protein function in cellular processes such as nuclear transport, transcriptional regulation, apoptosis and protein stability. All SUMO proteins localize to the nucleus and are covalently conjugated, affecting protein structure, function and interactions. SUMO2 and 3 are 96% identical and are more mobile within nucleus relative to SUMO1. Specific functional differences between SUMO1 and SUMO2 and 3 remain to be identified. |
|||
![]() SUMO2/3 Antibody |
|||
25117-100ul | SAB | 100ul | 468 EUR |
![]() Xenopus SUMO2 Antibody |
|||
abx027062-400ul | Abbexa | 400 ul | 627.6 EUR |
![]() Xenopus SUMO2 Antibody |
|||
abx027062-80l | Abbexa | 80 µl | 343.2 EUR |
![]() Anti-SUMO2 antibody |
|||
STJ25749 | St John's Laboratory | 100 µl | 332.4 EUR |
Description: This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last two amino acids of the carboxy-terminus have been cleaved off. Numerous pseudogenes have been reported for this gene. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. |
|||
![]() Anti-SUMO2 antibody |
|||
STJ28142 | St John's Laboratory | 100 µl | 332.4 EUR |
Description: This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last two amino acids of the carboxy-terminus have been cleaved off. Numerous pseudogenes have been reported for this gene. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. |
|||
![]() Anti-SUMO2 antibody |
|||
STJ190176 | St John's Laboratory | 200 µl | 236.4 EUR |
Description: Unconjugated Rabbit polyclonal to SUMO2 |
|||
![]() Anti-SUMO2 antibody |
|||
STJ116151 | St John's Laboratory | 100 µl | 332.4 EUR |
Description: This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last two amino acids of the carboxy-terminus have been cleaved off. Numerous pseudogenes have been reported for this gene. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. |
|||
![]() SUMO2/3 Antibody |
|||
F42018-0.08ML | NSJ Bioreagents | 0.08 ml | 165 EUR |
![]() SUMO2/3 Antibody |
|||
F42018-0.4ML | NSJ Bioreagents | 0.4 ml | 379 EUR |
![]() SUMO2/3 Antibody |
|||
F42027-0.08ML | NSJ Bioreagents | 0.08 ml | 165 EUR |
![]() SUMO2/3 Antibody |
|||
F42027-0.4ML | NSJ Bioreagents | 0.4 ml | 389 EUR |
![]() SUMO2 Antibody (Xenopus) |
|||
F42523-0.08ML | NSJ Bioreagents | 0.08 ml | 165 EUR |
![]() SUMO2/3 Antibody |
|||
F42562-0.08ML | NSJ Bioreagents | 0.08 ml | 165 EUR |
![]() SUMO2/3 Antibody |
|||
F42562-0.4ML | NSJ Bioreagents | 0.4 ml | 389 EUR |
![]() SUMO2/3 Antibody |
|||
RQ6517 | NSJ Bioreagents | 100ug | 419 EUR |
Description: Small ubiquitin-related modifier 2/3 is a protein that in humans is encoded by the SUMO2/3 gene. This gene encodes a protein that is a member of the SUMO (small ubiquitin-like modifier) protein family. It functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. It is not active until the last two amino acids of the carboxy-terminus have been cleaved off. Numerous pseudogenes have been reported for this gene. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. |
|||
![]() SUMO2/3 Antibody |
|||
V2257-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease. |
|||
![]() SUMO2/3 Antibody |
|||
V2257-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease. |
|||
![]() SUMO2/3 Antibody |
|||
V2257IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
Description: This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease. |
|||
![]() SUMO2/3 Antibody |
|||
V2257SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease. |
|||
![]() SUMO2/3 Antibody |
|||
V7091-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer�s disease. |
|||
![]() SUMO2/3 Antibody |
|||
V7091-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer�s disease. |
|||
![]() SUMO2/3 Antibody |
|||
V7091IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer�s disease. |
|||
![]() SUMO2/3 Antibody |
|||
V7091SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer�s disease. |
|||
![]() SUMO2/3 Antibody |
|||
V9080-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: This mAb reacts with both SUMO-2 and SUMO-3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() SUMO2/3 Antibody |
|||
V9080-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: This mAb reacts with both SUMO-2 and SUMO-3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() SUMO2/3 Antibody |
|||
V9080IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
Description: This mAb reacts with both SUMO-2 and SUMO-3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() SUMO2/3 Antibody |
|||
V9080SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: This mAb reacts with both SUMO-2 and SUMO-3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. |
|||
![]() Sumo2/ Rat Sumo2 ELISA Kit |
|||
ELI-52173r | Lifescience Market | 96 Tests | 1063.2 EUR |
![]() SUMO2 siRNA |
|||
20-abx935666 | Abbexa |
|
|
![]() SUMO2 siRNA |
|||
20-abx935667 | Abbexa |
|
|
![]() SUMO2 protein |
|||
30R-1289 | Fitzgerald | 100 ug | 321.6 EUR |
Description: Purified recombinant Human SUMO2 protein |
|||
![]() SUMO2 protein |
|||
30R-2786 | Fitzgerald | 100 ug | 403.2 EUR |
Description: Purified recombinant Human SUMO2 protein |
|||
![]() SUMO2 siRNA |
|||
20-abx905375 | Abbexa |
|
|
![]() pENTR223-SUMO2 |
|||
PVT12374 | Lifescience Market | 2 ug | 469.2 EUR |
![]() SUMO2 Antibody, HRP conjugated |
|||
1-CSB-PA05009B0Rb | Cusabio |
|
|
Description: A polyclonal antibody against SUMO2. Recognizes SUMO2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
SUMO2 Rabbit Polyclonal Antibody